226950.KQ

OliX Pharmaceuticals,Inc [226950.KQ] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

226950.KQ Stock Summary

Top 10 Correlated ETFs

226950.KQ


Top 10 Correlated Stocks

226950.KQ


In the News

226950.KQ Financial details

Company Rating
Strong Buy
Market Cap
250.2B
Income
-19.1B
Revenue
17.06B
Book val./share
3112.06
Cash/share
1618.29
Dividend
-
Dividend %
-
Employees
73
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-8.69
Forward P/E
-
PEG
10.17
P/S
36.9
P/B
5.82
P/C
10.29
P/FCF
-7.67
Quick Ratio
0.82
Current Ratio
0.96
Debt / Equity
0.73
LT Debt / Equity
0.7
-
-
EPS (TTM)
-1.3K
EPS next Y
-
EPS next Q
-
EPS this Y
-6.95%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
3.73%
Revenue last 5Y
72.1%
Revenue Q/Q
418.79%
EPS Q/Q
-157.65%
-
-
-
-
SMA20
1.54%
SMA50
2.45%
SMA100
20.78%
Inst Own
-
Inst Trans
-
ROA
-27%
ROE
-53%
ROC
-0.41%
Gross Margin
98%
Oper. Margin
-366%
Profit Margin
-377%
Payout
-
Shs Outstand
16.46M
Shs Float
11.82M
-
-
-
-
Target Price
-
52W Range
12900.0-25950.0
52W High
-35.84%
52W Low
+29.07%
RSI
51
Rel Volume
0.5
Avg Volume
127.89K
Volume
63.91K
Perf Week
9.54%
Perf Month
18.34%
Perf Quarter
7.01%
Perf Half Y
6.73%
-
-
-
-
Beta
0.816
-
-
Volatility
559%, 940.98%
Prev Close
3.03%
Price
16650
Change
-1.01%

226950.KQ Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
86.8188.13268.48680.161.18K
Net income per share
-1.1K-1.47K-2.17K-1.42K-1.32K
Operating cash flow per share
-824.26-285.82-1.39K-2.24K-1.47K
Free cash flow per share
-907.03-374.14-3.31K-2.42K-2.1K
Cash per share
2.73K5.18K3.64K4.52K1.8K
Book value per share
3.21K3.44K1.35K4.81K3.46K
Tangible book value per share
3.1K3.26K1.26K4.68K3.49K
Share holders equity per share
3.21K3.44K1.35K4.81K3.46K
Interest debt per share
1.631.1K2.9K3.15K2.77K
Market cap
414.09B418.24B561.13B291.88B219.18B
Enterprise value
409.36B421.44B564.06B330.94B246.56B
P/E ratio
-28.85-21.58-18.88-14.97-11.47
Price to sales ratio
366.34169.04152.7131.3212.84
POCF ratio
-38.58-111.26-29.45-9.51-10.35
PFCF ratio
-35.06-84.99-12.38-8.79-7.25
P/B Ratio
9.919.2430.34.434.4
PTB ratio
9.919.2430.34.434.4
EV to sales
362.16170.33153.5135.5114.45
Enterprise value over EBITDA
-28.54-28-24.94-16.22-15.86
EV to operating cash flow
-38.14-112.11-29.6-10.79-11.65
EV to free cash flow
-34.66-85.64-12.44-9.96-8.15
Earnings yield
-0.03-0.05-0.05-0.07-0.09
Free cash flow yield
-0.03-0.01-0.08-0.11-0.14
Debt to equity
00.322.010.610.73
Debt to assets
00.180.430.30.35
Net debt to EBITDA
0.33-0.21-0.13-1.91-1.76
Current ratio
13.5915.381.291.644.9
Interest coverage
-2.7K-67.94-9.97-7.64-5.21
Income quality
0.750.190.651.091.11
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.160.090.10.050
Research and developement to revenue
7.943.833.871.771.04
Intangibles to total assets
0.030.030.020.020
Capex to operating cash flow
0.10.311.380.080.43
Capex to revenue
-0.95-0.47-7.15-0.27-0.53
Capex to depreciation
-1.39-0.97-16.27-1.28-3.43
Stock based compensation to revenue
0.950.210.510.150
Graham number
8.92K10.69K8.13K12.41K10.14K
ROIC
-0.36-0.26-0.42-0.2-0.21
Return on tangible assets
-0.33-0.25-0.35-0.15-0.19
Graham Net
2.51K2.69K-1.24K-247.26-1.55K
Working capital
34.69B64.56B11.87B25.5B25.58B
Tangible asset value
40.4B42.82B17.27B64.1B50.34B
Net current asset value
34.04B35.82B-15.03B-1.4B-20.35B
Invested capital
00.322.010.610.73
Average receivables
271.52M529.74M535.16M849.5M3.22B
Average payables
01100
Average inventory
500.33M335M339.15M515.65M562.79M
Days sales outstanding
174.7176.4854.8244.92113
Days payables outstanding
00000
Days of inventory on hand
125.5280.1416.34121.5864.71
Receivables turnover
2.094.776.668.133.23
Payables turnover
0692.64M000
Inventory turnover
2.914.5522.3435.64
ROE
-0.34-0.43-1.6-0.3-0.38
Capex per share
-82.77-88.32-1.92K-184.97-628.46

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
50.55135.09165.75142.21655.81
Net income per share
482.32-509.02-645.58-345.96199.43
Operating cash flow per share
-624.58-453.19-496.86-417.49-51.72
Free cash flow per share
-673-558.51-679.21-509.27-270.03
Cash per share
4.52K3.16K3.08K2.2K1.62K
Book value per share
4.81K3.33K3.07K2.87K3.11K
Tangible book value per share
4.68K3.23K2.95K2.76K3.14K
Share holders equity per share
4.81K3.33K3.07K2.87K3.11K
Interest debt per share
2.99K2.49K3.08K2.94K2.33K
Market cap
291.88B373.38B233.62B228.55B243.34B
Enterprise value
330.94B409.97B272.4B265.84B270.71B
P/E ratio
11.04-10.98-6.59-11.619.04
Price to sales ratio
421.32165.45102.62112.8623.16
POCF ratio
-34.1-49.32-34.24-38.44-293.71
PFCF ratio
-31.65-40.02-25.04-31.52-56.25
P/B Ratio
4.436.715.545.64.88
PTB ratio
4.436.715.545.64.88
EV to sales
477.72181.66119.66131.2825.77
Enterprise value over EBITDA
-134.37-57.12-39.33-60.7492.19
EV to operating cash flow
-38.67-54.15-39.92-44.72-326.75
EV to free cash flow
-35.89-43.94-29.2-36.66-62.58
Earnings yield
0.02-0.02-0.04-0.020.01
Free cash flow yield
-0.03-0.02-0.04-0.03-0.02
Debt to equity
0.610.730.9810.73
Debt to assets
0.30.330.380.40.35
Net debt to EBITDA
-15.86-5.1-5.6-8.529.32
Current ratio
1.641.411.150.964.9
Interest coverage
-4.11-9.24-8.57-5.62.64
Income quality
4.260.890.771.21-0.26
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.170.040.050.060
Research and developement to revenue
0.242.522.041.430.42
Intangibles to total assets
0.020.020.020.020
Capex to operating cash flow
0.080.230.370.224.22
Capex to revenue
-0.96-0.78-1.1-0.65-0.33
Capex to depreciation
-1.19-2.75-3.74-1.96-5.25
Stock based compensation to revenue
0.670.240.240.160
Graham number
7.22K6.18K6.68K4.72K3.74K
ROIC
-0.02-0.09-0.09-0.060.03
Return on tangible assets
0.05-0.07-0.08-0.050.03
Graham Net
-247.26-722.43-1.57K-1.93K-1.4K
Working capital
25.5B17.19B5.97B-1.42B25.58B
Tangible asset value
64.1B53.97B40.53B39.28B50.34B
Net current asset value
-1.4B-9.1B-19.65B-25.64B-20.35B
Invested capital
0.610.730.9810.73
Average receivables
1.07B2.69B3.17B2.02B3.61B
Average payables
000.50.50
Average inventory
554.99M666.64M678.43M689.06M582.88M
Days sales outstanding
149.03169.0782.9386.2145.26
Days payables outstanding
00000
Days of inventory on hand
105.9795.1991.5794.0563.27
Receivables turnover
0.60.531.091.041.99
Payables turnover
00669.07M00
Inventory turnover
0.850.950.980.961.42
ROE
0.1-0.15-0.21-0.120.06
Capex per share
-48.42-105.32-182.35-91.78-218.31

226950.KQ Frequently Asked Questions

What is OliX Pharmaceuticals,Inc stock symbol ?

OliX Pharmaceuticals,Inc is a KR stock and trading under the symbol 226950.KQ

What is OliX Pharmaceuticals,Inc stock quote today ?

OliX Pharmaceuticals,Inc stock price is $16650 today.

Is OliX Pharmaceuticals,Inc stock public?

Yes, OliX Pharmaceuticals,Inc is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap